Unlike KEYNOTE‐028 study, the trail (NCT02443324) recruited both PD-L1+ and PD‐L1− patients, in which 46.2% of PD-L1 patients underwent tumor recurrence or metastasis. This evidence concerns the gene CD274 and neoplasm.